Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Demand Status 2019 | Industry Analysis by Major Companies, Regions, Opportunities, and Forecast to 2024

Press Release

Dipeptide Peptidase 4 (DPP-4) Inhibitors

Report Titled: “Dipeptide Peptidase 4 (DPP-4) Inhibitors Market – Growth, Trends, and Forecast (2019 – 2024)

The Dipeptide Peptidase 4 (DPP-4) Inhibitors Market report 2019 provides complete information of key players across the globe. Company provides detailed analysis of market and future aspects of “Dipeptide Peptidase 4 (DPP-4) Inhibitors Market”. The report focuses on critical and significant data which makes the research a very important tool for experts, analysts and managers to get ready-to-access analysis.

Scope of the Report:

  • The DPP-4 inhibitors market is segmented by brands and covers the following brands: Januvia, Onglyza/Kombiglyze, Tradjenta, Nesina, Galvus, and other brands. The report is segmented into five regions: North America, Asia-Pacific, Middle East & Africa, Latin America, and Europe.

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999746

    Market Overview:

  • The global DPP-4 inhibitors market was valued at USD 10.5 billion in 2018 and is expected to record a CAGR of 4% during 2019-2024. The North American DPP-4 drugs segment of the market studied accounted for the highest revenue, in 2018, and Latin America is expected to register the highest CAGR, of approximately 6%, during the forecast period.
  • Increasing diabetes type-2 and obesity populations will drive the growth of the market in the forecast period.
  • Increase in clinical trials on the DPP-4 drugs will also boost the market growth in the forecast period.<

    Market Dynamics: –

    • Drivers: (Developing regions and growing markets)
    • Limitations: (Regional, Key Player facing Issues, Future Barriers for growth)
    • Opportunities: (Regional, Growth Rate, Competitive, Consumption)

    The report provides key statistics on the market status of the Dipeptide Peptidase 4 (DPP-4) Inhibitors Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Dipeptide Peptidase 4 (DPP-4) Inhibitors.

    Enquire Before Purchasing this Report – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999746

    Key Market Trends: – The Tradjenta Market will Surpass Merck’s Januvia During the Forecast Period

    The global Tradjenta market is expected to register a CAGR of 5.7 %, during the forecast period, 2019-2024, and is expected to surpass the Januvia market, which held the maximum market share in 2018. The Tradjenta market includes its combination Jentadueto and Jentadueto XR, a combination of linagliptin (Tradjenta) and metformin hydrochloride, for use in the treatment of type 2 diabetes. The type-2 diabetes drug, Tradjenta (linagliptin) was not launched in Germany, because of a decision by the county’s reimbursement authority, which concluded that it doesn’t provide any additional benefits, compared to the medicines already on the market.

    North America Holds the Highest Market Share

    The Asia-Pacific holds 32% of the market share in the global DPP-4 market, followed by North America, which holds the highest market share. Increasing diabetes prevalence in established and emerging countries is expected to drive the market. This increase, over the years, is due to the overall effect of individual-level factors, like an increasing median age of the population and health factors, including obesity and inactivity levels among people.
    Lowering birth rates, along with increasing life expectancy in countries like Japan, Italy, Germany, and France, which have a high percentage of the geriatric population, are expected to drive the growth of the market.

    For Detailed TOC, Click Here: https://www.industryresearch.co/TOC/13999746#TOC

    Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Report Also Covers Marketing Strategy Analysis, Top Manufacturers:

  • Merck And Co.
  • AstraZeneca
  • Bristol Myers Squibb
  • Novartis
  • Takeda Pharmaceuticals
  • Eli Lilly
  • Boehringer Ingelheim

    What Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Report Provides:

    • Value chain analysis
    • Ecosystem analysis
    • Key players in ecosystem
    • Report highlights top manufacturers/suppliers/providers
    • Analysis of portfolio
    • Key distributors

    Some Major Points Covered in Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Report:

    • Introduction and Market Overview
    • Industry Chain Analysis
    • Market, by Type
    • Market, by Application
    • Production, Value ($) by Region (2014-2019)
    • Production, Consumption, Export, Import by Regions (2014-2019)
    • Market Status and SWOT Analysis by Regions
    • Competitive Landscape
    • Analysis and Forecast by Type and Application
    • Analysis and Forecast by Region
    • New Project Feasibility Analysis
    • Research Finding and Conclusion

    Purchase this Report (Price 5000 USD for single user license) – https://www.industryresearch.co/purchase/13999746

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    LED Industrial Lighting Industry Global Market Size, Share, Supply, Demand, Segments and Forecast 2019-2025

    Niacinamide Market 2019 Global Industry Size, Outlook, Share, Demand, Manufacturers and 2025 Forecast Research’s

    Supply Chain Big Data Analytics Market 2019-2024 Top Countries Data, Business Expansion Plans, Present Demands, Driving Factors, Rising Status of Key Players